Register now to learn about a new option for relapsed or refractory follicular lymphoma

General Discussions

ASCO Offers Resources for You and Your Patients

Lisa Schulmeister, RN, MN, APRN-BC, OCN®, FAAN Editor-in-Chief OncLive Nursing Oncology Nursing Consultant, Adjunct Assistant Professor of Nursing Louisiana State Health Sc...

Nurses Have Key Role in Managing Side Effects of Maintenance Therapy

Susan J. Keen, RN, OCN Deborah L. Selm-Orr, RN, MS, CRNP, AOCN What is the value of maintenance therapy in patients with lung or breast cancers, and how and when should it be used? ...

Colleen Jennings on Improving Follow-Up Phone Calls

Colleen Jennings, RN, BSN, HN-BC, of Cancer Treatment Centers of America at Eastern Regional Medical Center, discusses the initiative their center took to improve discharge follow-up calls. The ...

Promoting Sleep in Children With Cancer

Rebecca Kronk, PhD, CRNP, MSN   Assistant Professor, Duquesne University School of Nursing Over the past decade, evidence has mounted recognizing sleep disturbances an...

Knowing the Signs: Recognizing Depression in African Americans With Cancer

Amy Zhang, PhD A new study has found that African American patients with cancer feel and describe depression differently than their Caucasian counterparts. Findings from a pilot study, pos...

Treatment of Depression and Fatigue in Cancer Survivors Needs Improvement

Cancer and its treatments can bring a number of adverse events (AEs), and as more patients are living longer after their treatment, these effects can become long-lasting. Often, oncology nurses are...

FDA Approves Crizotinib for Pediatric/Young Adult ALK+ Anaplastic Large Cell Lymphoma

The FDA has approved crizotinib (Xalkori) for the treatment of pediatric patients 1 year of age and older and young adults with ALK-positive relapsed or refractory, systemic anaplastic large c...

More Targets Discovered, More Molecular Testing Needed in Lung Cancer

Molecular testing is a critical component of the treatment selection process in lung cancer, as a host of effective drugs have since been developed to target alterations such as ALK, ROS1...

External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.